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ABSTRACT 
 
Dengue virus (DENV) infections are expanding worldwide and, because of the lack of a vaccine, the 
search for antiviral products is imperative. It would be interesting to develop 
an antiviral product that can interact with dengue virus(DENV)  or its receptor, prevent host cell 
infection and subsequent immune activation. DENVentry is thus an interesting target for antiviral 
therapy. DENV enters the host cell through receptor-mediated endocytosis. Several cellular receptors 
have been proposed, and DC-SIGN(CD209), present on dendritic cells, is considered as the most 
important DENVreceptor until now. Because DENV entry is a target for antiviral therapy, various 
classes of compounds have been investigated to inhibit this process. The Carbohydrate Binding 
Agents(CBAs) are considered effective against inhibiting viral entry  into the host cell. 
In this project, various CBAs like Hippeastrum hybrid (HHA), Galanthus nivalis (GNA), and Urtica 
dioica (UDA) along with their analogues are used as ligands for the DENV receptor present on the 
dendritic cells (DCs). Using AutoDock vina, we find their binding energy with the receptor and thus 
determine an effective CBA and hence a potential drug against the desease. The UDA molecule 
shows high affinity for the DC-SIGN(CD209) receptor and hence can be used as an effective drug. 
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1. INTRODUCTION 
 
Dengue virus is an expanding public health problem in tropical and subtropical regions of the world, 
mainly owing to failure in the maintenance of control programs for the mosquito vector Aedes 
aegypti and increasing and unplanned urbanization. It has been estimated that over 50 million dengue 
virus infections of varying severity occur globally each year, making this virus the most significant 
mosquito-borne human pathogen.  
 
Dengue virus (DENV) is a single-stranded, positive-sense enveloped RNA virus of the Flaviviridae 
family that is transmitted by Aedes aegypti and Aedes albopictus. There are four antigenically related 
but distinct serotypes of dengue virus, designated DEN-1, DEN-2, DEN-3, and DEN-4, and infection 
by any one serotype does not protect the individual from infection by the remaining three serotypes. 
Each serotype shares around 65% of the genome, and, despite of the differences, each serotype 
causes nearly identical syndromes in humans and circulates in the same ecological niche . Dengue 
virus causes clinical syndromes in humans, ranging from an acute self-limited febrile illness (dengue 
fever, DF) to a severe and life-threatening vascular leakage and shock (dengue hemorrhagic 
fever/dengue shock syndrome, DHF/DSS). It has been postulated that hemorrhagic fever or shock 
syndrome is usually the result of sequential infection with multiple serotypes In the last decade, due 
to a decline of vector control efforts, DENV has reemerged in tropical areas and is considered as the 
most common arthropod-borne tropical disease that endangers an estimated 2.5 billion people. Every 
year, 50 million infections occur, including 500,000 hospitalizations for DHF, mainly among 
children, with a case fatality rate exceeding 5% in some areas. 
Despite the importance and increasing incidence of DENV as a human pathogen, there are no 
antiviral agents or vaccines available for treatment or prevention, and little is known about the cell 
biology or the life cycle of DENV in mosquitos or mammalian cells. The development of a 
successful chemotherapy for DENV infection requires a better understanding of the viral life cycle to 
elucidate potential targets and, thus, to obtain key information for the rational design of antiviral 
drugs.  
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1.1.1 Structure Of Dengue Virus  
 
The dengue virus surface is composed of 180 copies of the envelope glycoprotein and the membrane 
protein. The E protein of dengue virus contains a class II fusion peptide sequence that is important 
for viral invasion of a host cell. There are remarkable structural deviations between the immature and 
mature dengue envelopes as revealed by elegant cryo-electron microscopy studies. The immature 
dengue virus particle is covered with 60 asymmetric trimers of prM-E heterodimers that stick out like 
spikes from its surface. The prM protein protects E from premature fusion while passing through the 
acidic environment of the trans-Golgi network (TGN) during morphogenesis. During maturation, the 
Nterminal part of the prM protein is released by the host cell furin that induces a rearrangement of 
the E proteins essential for fusion. In the mature virus, the E proteins exist as homodimers that lie on 
the viral membrane in the form of 30 so-called “rafts”. Each raft contains three parallel dimers 
arranged in icosahedral symmetry and organized into a herringbone pattern. 
 
 
 
 
 
 
  
Figure 1 Structure of a dengue virus 
 
 
 
 
3 | P a g e  
 
 
 
  
CHAPTER 2 
 
LITERATURE REVIEW 
4 | P a g e  
 
2. LITERATURE REVIEW 
 
2.1 Mechanism Of Dengue Virus Entry Into The Host Human Cell And Its Effect On 
Human Immune System  
 
The infectious entry of DENV in its target cells, mainly dendritic cells, monocytes, and 
macrophages, is mediated by the viral envelope glycoprotein E via receptor-mediated endocytosis . 
The E-protein is the major component (53 kDa) of the virion surface and is arranged as 90 
homodimers in mature virions. DENV enters its host cell via clathrin-mediated endocytosis, 
comparable with other flaviviruses . However, DENV entry via a nonclassical endocytic pathway 
independent from clathrin has also been described. It seems that the entry pathway chosen by DENV 
is highly dependent on the cell type and viral strain. In case of the classical endocytic pathway, there 
is an uptake of the receptor-bound virus by clathrin-coated vesicles. These vesicles fuse with early 
endosomes to deliver their cargo into the cytoplasm. The Eprotein responds to the reduced pH of the 
endosome with a large conformational rearrangement. The low pH triggers dissociation of the E-
homodimer, which then leads to the insertion of the fusion peptide into the target cell membrane 
forming a bridge between the virus and the host. Next, a stable trimer of the E-protein is folded into a 
hairpin-like structure and forces the target membrane to bend towards the viral membrane, and 
eventually fusion takes place. The fusion results in the release of viral RNA into the cytoplasm for 
initiation of replication and translation  
 
 
Figure 2: A dengue virus life cycle 
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Once it is released into the cell cytoplasm, the nucleocapsid opens to uncoat the viral genome. This 
process releases the viral RNA into the cytoplasm. The viral RNA then hijacks the host cell's 
machinery to replicate itself. The virus uses ribosomes on the host's rough endoplasmic reticulum 
(ER) to translate the viral RNA and produce the viral polypeptide. This polypeptide is then cut to 
form the ten dengue proteins. The newly synthesized viral RNA is enclosed in the C proteins, 
forming a nucleocapid. The nucleocapsid enters the rough ER and is enveloped in the ER membrane 
and surrounded by the M and E proteins. This step adds the viral envelope and protective outer layer. 
The immature viruses travel through the Golgi apparatus complex, where the viruses mature and 
convert into their infectious form. The mature dengue viruses are then released from the cell and can 
go on to infect other cells. 
As the adaptive immune response starts fighting the dengue infection, B cells produce antibodies 
called IgM and IgG that are released in the blood and lymph fluid, where they specifically recognize 
and neutralize the dengue viral particles. In another adaptive immune response, cytotoxic T cells, or 
killer T cells, recognize and kill the cells that are infected with the dengue virus. The innate immune 
response activates the complement system, a response that helps the antibodies and white blood cells 
remove the virus. Together, the innate and adaptive immune responses neutralize the dengue 
infection, and the patient recovers from dengue fever.  
After recovering from a first dengue infection, a person is protected from infection with the 
remaining three dengue serotypes for two to three months. Unfortunately, it is not long-term 
protection, and after that short period, a person can be infected with any of the remaining three 
dengue serotypes.  
When a person is infected with a second dengue serotype antibodies from the first infection actually 
help spread the dengue viral infection and increase viremia, the amount of virus in the bloodstream  
instead of destroying the virus, the existing antibodies and the antibodies newly produced by the 
memory B cells can actually help the virus infect host cells more efficiently. Ironically, the 
consequence of antibody-dependent enhancement is that the body's immune system response actually 
makes the clinical symptoms of dengue worse and raises the risk of severe dengue illnesses.  
during a second infection with dengue, the cytotoxic T cells produced by the immune system provide 
only partial immunity against the new dengue serotype. The cytotoxic T cells do not effectively clear 
the virus from the body, and they release excess quantities of molecules called cytokines. In normal 
quantities, cytokines help the immune response; however, in high quantities, cytokines can produce 
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serious inflammation and tissue damage such as leakage from the capillaries, possibly contributing to 
the development of severe dengue diseases. 
 
 
  
Figure 3: Model of antibody-dependent enhancement of dengue infection 
 
 
 
2.2 Strategy For Inhibtion Of Dengue Virus Interaction With The Host Cell  
 
There are four stages of the viral life cycle, and each stage can be considered for the development of 
drugs. In stage 1, prevent viral entry or infection of the host cell, or inhibit fusion of the viral 
envelope with the host vesicles. The E protein can be taken as an ideal target. In stage 2, prevent 
maturation processing of the individual viral protein. The well-studied viral protease is considered a 
good target. In stage 3, prevent viral RNA synthesis by inhibiting the viral helicase and RdRp. 
Finally, in stage 4, target the host proteins such as furin and signalase that help the maturation and 
release of infectious viral particles.   
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2.3 Human Cell DENV Attachment And Receptors. 
Prior to fusion, DENV needs to attach to specific cellular receptors. The virus must interact with a 
wide variety of cellular receptors. 
Inhibiting the DENV entry into host cells can be achieved by inhibiting the DENV receptors present 
on the cells involved in the fusion process in which the viral genome is injected into the host cell. 
 
  
Table 1: Different human cell DENV attachment and receptors. 
 
Cell type Cell description DENV receptor(s) 
 
Monocytes 
 
 
Primary myeloid cells 
 
CD14/LPS 
HSP70/HSP90 
Fc-receptor 
 
Dendritic cells 
 
Primary myeloid cells 
 
DC-SIGN 
 
Macrophages 
 
Primary myeloid cells 
 
Mannose receptor 
CLEC5A 
 
Huh 
 
Hepatocytes 
 
HS 
 
HepG2 
 
Hepatocytes 
 
Laminin receptor, GRP78, HS 
 
2.4 Dendritic Cells (DC-SIGN receptor) 
 
The primary DENV target cells in the skin are believed to be immature dendritic cells (DCs) or 
Langerhans cells. Immature DCs are very efficient in capturing pathogens whereas mature DCs are 
relatively resistant to infection. The search for cellular receptors responsible for DENV capture leads 
to the identification of cell-surface C-type lectin DC-specific intercellular adhesion molecule 3-
grabbing nonintegrin (DC-SIGN; CD209. DC-SIGN, mainly expressed by immature DC as a 
tetramer, is a member of the calcium-dependent C-type lectin family and is composed out of four 
domains: a cytoplasmic domain responsible for signaling and internalization due to the presence of a 
8 | P a g e  
 
dileucine motif, a transmembrane domain, seven to eight extracellular neck repeats implicated in the 
oligomerization of DC-SIGN, and a carbohydrate recognition domain (CRD). The CRD recognizes 
high-mannose N-glycans and fucose-containing blood group antigens. Following antigen capture in 
the periphery, DCs maturate by upregulation of the costimulatory molecules and migrate to 
secondary lymphoid organs Activated DCs are stimulators of naive T cells and they initiate 
production of cytokines and chemokines [85]. Inhibition of the initial interaction between DENV and 
DC could prevent an immune response. DC-SIGN could be a target for antiviral therapy by 
interrupting the viral entry process. 
Carbohydrate-binding agents (CBAs) have been shown to prevent capture of DENV to the DC-SIGN 
receptor on the dendritic cell.  
 
 
 
2.5 Potential Ligand Molecules (CBAs). 
 
Hippeastrum hybrid (HHA), Galanthus nivalis (GNA), and Urtica dioica (UDA), isolated from the 
amaryllis, snowdrop, and stinging nettle respectively, and their analogues, are the CBAs used as 
ligands to inhibit the activity of the DC-SIGN receptor during DENV fusion into the dendritic cells.  
 
Table 2: Ligand molecule (CBAs) 
 
Sr. No. 
 
PUBCHEM ID 
 
ALSO KNOWN AS 
 
2D STRUCTURE 
1.  
CID 60855 
 
Zanamivir 
(GNA) 
 
2.  
CID 58974096 
 
Talo-zanamivir 
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3.  
CID 59464423 
 
SureCN12367840 
 
 
4.  
CID 60076457 
 
 
 
5.  
CID 71753010 
 
Zanamir-d3 
 
 
6.  
CID 448825 
 
Hippeastrum hybrid 
(HHA) 
 
 
7.  
CID 17754024 
 
CHEBI:60840 
 
 
8.  
CID 23422347 
 
CTK0H0810 
 
 
9.  
CID 46936304 
 
SureCN4317430 
 
 
10.  
CID 49852385 
 
CPD-9518 
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11.  
CID 448003 
 
 
Urtica dioica  
(UDA) 
 
12.  
CID 25245790 
 
 
13.  
CID 49852303 
 
UDP-N-acetylmuramate 
 
 
14.  
CID 53886465 
 
 
15.  
CID 73350364 
 
CHEMBL2374461 
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3. MATERIALS AND METHODS 
 
3.1 Tools And Softwares 
 
 
Computational biology and Bioinformatics have the potential to speed up drug discovery processes, 
reducing the costs of the processes and changing the way the drugs are designed. Rational drug 
design facilitates and speeds up the drug designing processes that involves various method of 
identifying novel compounds. One advanced method is the docking of the drug molecule or ligand or 
inhibitor with the target. The site where the drug binds is known to the site of action, which is 
responsible for the pharmaceutical effect is the target. Docking is the method by which two 
molecules bind to each other in 3D space. There are various tools, software and servers meant for 
docking calculations. 
 
3.1.1 Softwares used are 
 
 Swiss-Pdb Viewer 
 Argus Lab 4.0.1 
 AutoDockTools-1.5.6rc 
 Auto Dock Vina 1.0 
 Chimera 1.8.1 
 MGL Tools 1.5.6 
 Open Babel GUI 
 Pymol 
 
 
3.1.2 Online servers used 
 
 https://pubchem.ncbi.nlm.nih.gov 
 http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index 
 http://bioserver-3.bioacademy.gr/Bioserver/ChemBioServer/Toxic.php 
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3.1.3 Files required for docking 
 
 FASTA sequence of all the CD209 isoforms. 
 3D structure and “.pdb” format file of these isoforms. 
 “.sdf” format file of all the inhibitors. 
 “.sdf” format file converted to “.pdb” format using Open Babel GUI. 
 “.pdbqt” files of both, the proteins as well as the ligand molecules. 
 
 
3.2 Procedure 
 
 FASTA sequence of all the CD209 isoforms obtained from NCBI. 
 3D structure and “.pdb” format file of these isoforms obtained from PHYRE2. 
 In chimera 1.8.1, energy minimization of all the 3D structures of protein molecules was done and 
saved in “.pdb” format 
 ArgusLab 4.0 was used for geometric optimization of these molecules to avoid any error in 
docking. 
 Using AutoDock tools 1.5.6, “.pdb” files of proteins were converted to “.pdbqt” format. 
 3D structures of the ligands were obtained from PubChem. (in “.sdf” format) 
 Using Open Babel GUI, “.sdf” format to “.pdb” format 
 “.pdb” format of the ligands were converted to “.pdbqt” format using AutoDock tools 1.5.6 
 Molecular docking was done using Autodock vina. 
 Results from it were saved in “.pdbqt” format 
 Results then, were then viewd in PYMOL. 
 Toxicity of the results was analyzed in ChemBioserver. 
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3.3 Methodolgy 
 
Molecular docking is a method which is used for the prediction of preferred orientation of one 
molecule to other molecule when bound form a stable. It is frequently used to predict the binding 
energy of small molecular drugs to the targeted protein in order to predict affinity and activity. 
 
3.3.1 Retrieval of amino acid sequences of CD209 protein isoforms from NCBI: 
 
NCBI stands for National Centre for Biotechnological Information. It is established as a division of 
National Library of Medicines at National Institutes of Health. The NCBI responsible for creating 
automated systems of knowledge about molecular biology, biochemistry, and genetics, providing the 
use of such databases and software by the research and medical community; collect biotechnology 
information both nationally and internationally; and execution research on advanced methods of 
computer-based information processing for examining the structure and function of biologically 
important molecules. The URL for this database is  http://www.ncbi.nlm.nih.gov. 
 
 The above mentioned URL was browsed. 
 In the left search panel “protein” was selected, and in the right search panel “CD209 isoform” 
was typed and searched. 
 FASTA sequence of “CD209 isoform 1”, “CD209 isoform 3”, “CD209 isoform 4” and 
“CD209 isoform 5” were obtained and saved in notepad. 
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Figure 4:  A sample FASTA format sequence 
 
 
3.3.2 Retrieval of 3D structure of PKM2 Protein modelled by PHYRE2 
 
PHYRE is an automatic fold recognition server for calculating the structure and function of the 
protein sequence that got submitted in the server. It is used for academic users only. It uses the 
principle and technique of Homology Modelling and relies on Hidden Markov Models. 
 
 The FASTA sequence, displaying the amino acid sequence, of each of the CD209 
isoform was pasted in “amino acid sequence” tab. 
 In the “modelling mode” section, “normal” option was checked. 
 “Phyre search” was clicked. 
 After some time the results were sent to the user given email address. 
 The modelled structure was retrieved from the link sent by the server in “.pdb” format. 
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Figure 5: A view of PHYRE2 website 
 
3.3.3 Energy minimization of all 3D structure of proteins by Chimera 1.8.1: 
 
UCSF CHIMERA 1.7 is an extensible programme for visualization and analysis of molecular 
structure and related data including density maps, supramolecular associations, sequence 
alignments, docking results, routes and conformational ensembles. One of the best features is the 
structural editing job. It can minimize the energy of molecules providing them high stability. 
 
 Chimera window was opened. 
 From the option, the 3D structure of protein was retrieved. 
 The total resideues were selected. 
 From the tool option, by the structure editing option, minimized structure option was clicked. 
 The minized structure was saved in “.pdb” format. 
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Figure 6: A view of Chimera 
 
 
3.3.4 Geometry Optimization of all 3D structure of proteins by ArgusLab: 
 
Argus Lab is one of the important software which is used for the geometry optimization of the 
Protein molecule which we need to dock. This is done because when we dock with the ligand 
molecules it gives a perfect result without any errors. It optimize the geometry of the molecule 
for better orientation 
 
     ArgusLab 4.0 window was opened 
     From the option file, the 3D structure of protein was retrieved 
     Then go to geometry optimization tools 
      From the tool option, by the structure editing option, Optimize geometry option was clicked. 
     The Optimized structure was saved in .pdb format 
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Figure 7: A view of ArgusLab 
 
 
3.3.5 Collect SDF files of CD209 Inhibitor molecules from PubChem: 
 
PubChem is a database of chemical structures of small organic molecules and contain information of 
their biological activity, origin and related literatures. It is executed and updated by NCBI and is 
freely available. Millions of compound structures and data seta can be freely downloaded in “.sdf” 
format. 
 PubChem page was retrieved by browsing Pubchem.ncbi.nlm.nih.gov 
 In search bar individual inhibitors name was typed and entered 
 All the available ligands of therapeutic target database retrieved in “.sdf” file format 
 
 
3.3.6 Conversion of .sdf file format to .pdb by Open Babel GUI: 
 
Open Babel 2.3.1 is a chemical toolkit designed to interpret the various language of chemical data. It 
allows searching, converting, and analyzing chemical data. It supports Cheminformatics, molecular 
modelling, and bioinformatics. It coverts chemical data from one file format to another. 
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 Open Babel 2.3.1 window was opened 
 The input format was selected as “.sdf” and the output format as “.pdb”. 
 From the input option “.sdf” file was browsed. 
 Click on the convert option to convert “.sdf” file format to “.pdb” file format. 
 Then the selected files were generated in the “.pdb” file format and saved. 
 
 
Figure 8: A view of OpenBabel GUI 
 
 
3.3.7 Conversion of .pdb to .pdbqt of Molecules Using Auto Dock Tools 1.5.6: 
 
Auto Dock 4.0 is an Interactive Molecular graphics program developed by The Scripps Research 
Institute for estimating docking calculations and displaying docking modes of pairs of protein and 
ligand molecules. Auto Dock is used as the docking tool which calculates intermolecular “energies” 
by adding up all intermolecular interactions, adding polar hydrogens and also the kollmann charges 
to the protein molecule (e.g. van der Waals, electrostatic) that occur between a ligand and protein 
target. 
 
 Then we open the “.pdb” file in Autodock tools (version 1.5.6) software.  
 We add hydrogen to the molecule (polar only).  
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  Go to grid          macromolecule          choose          save as “.pdbqt” file  
  Click on grid again and then click on grid box.  
 Then we set the desired values in grid box .  
  Next for the ligand we click on ligand          input         open         open the inhibitors “.pdb” 
file.  
  Go to ligand         torsion tree          choose torsions          done.  
 Click ligand          torsion tree          detect root.  
 Save the file by ligand          output         save as “.pdbqt”. 
 
 
 
Figure 9: Autodock tools (version 1.5.6) software 
 
 
3.3.8 Molecular Docking Using Auto DockVina: 
 
AutoDock Vina significantly improves the average accuracy of the binding mode 
predictions compared to AutoDock 1.5.6, judging by various tests according to The Scripps 
Research Institute the training set used in AutoDock 1.5.6 development. Additionally and 
independently, AutoDock Vina has been tested against a virtual screening benchmark called the 
Directory of Useful Decoys. 
 
21 | P a g e  
 
 
 Create a conf.txt file giving the information of configuration for the Docking process in the same 
folder where we have the protein and its inhibitor in the “.pdbqt” format. 
 
 
Figure 10: A sample conf.txt file 
 
 Open the Command prompt in the system. 
 Give the location where the “.pdbqt” files of both Protein and inhibitor in cmd. 
 Then give the location of program vina in the program file for processing. 
 Give the command in the cmd for docking procedure to initiate. 
 Result is displayed in the log file generated by the AutoDock Vina. 
 
 
Figure 11: Docking process in cmd 
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Figure 12: Docking result as log.txt file 
 
 
3.3.9 Toxicity Prediction by Chem Bio server: 
 
This is a Server which is part of the Bio academy Bio server that contains some tools and web 
services developed in the Biomedical Research Foundation of the Academy of Athens. Its main aim 
is to improve computational molecule screening and analysis and it is financed by the Greek Ministry 
of Education Cooperation Proposal Entitled as PIK3CA Oncogenic Mutations in Breast and Colon 
Cancers.  
a) The ligand molecule in either “.mol” or “.sdf” format is uploaded  
b) Then on clicking “Process Data” at the end of the page, it gives the result whether the compound 
is toxic or nontoxic.  
c) If the compound is toxic, it shows because of which molecule.  
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4. RESULTS 
 
4.1 3d Structures Of CD209 Antigen Isoforms Obtained From Phyre2. 
 
The Phyre2 servers predict the three-dimensional structure of a protein sequence using the principles 
and techniques of homology modeling. Following 3D structures of CD209 Isoforms were obtained 
from it: 
 
                                                            
         Figure 13: CD209 Isoform 1     Figure 14: CD209 Isoform 3 
      
 
                                                        
    Figure 15: CD209 Isoform 4     Figure 16: CD209 Isoform 5 
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4.2 Docking Results Of CD209 Isoforms With All The Inhibitors 
 
CD209 isoform 1, CD209 isoform 3, CD209 isoform 4 and CD209 isoform 5 were docked with all 
the inhibitors and the results were saved in “.txt” and “.pdbqt” format respectively, for further use. 
 First we use “.pdbqt” format of the results and visualize them in PYMOL. 
 Usinf “.txt” file , we analyze the affinity of the inhibitors with the protein site. 
 
4.2.1 Results of docking Inhibitors with CD209 Isoform 1 in AUTODOCK Vina: 
 
                                   
Table 3: CID 60855     Table 4: CID 58974096           Table 5: CID 59464423  Table 6: CID 60076457 
 
 
                               
Table 7: CID 71753010       Table 8: CID 448825        Table 9: CID 17754024     Table 10: CID 23422347 
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Table 11: CID 46936304             Table 12: CID 49852385               Table 13: CID 448003                  Table 14: CID 49852303 
 
 
                         
Table 15: CID 53886465        Table 16: CID 73350364             Table 17: CID 25245790 
 
4.2.2 Results of docking Inhibitors with CD209 Isoform 3 in AUTODOCK Vina: 
 
 
                                   
Table 18: CID 60855         Table 19: CID 58974096            Table 20: CID 59464423              Table 21: CID 60076457 
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Table 22: CID 71753010                Table 23: CID 448825                Table 24: CID 17754024              Table 25: CID 23422347 
 
 
                                            
Table 26: CID 46936304                Table 27: CID 49852385              Table 28: CID 448003  Table 29: CID 49852303 
 
 
 
                             
Table 30: CID 53886465       Table 31: CID 73350364               Table 32: CID 25245790 
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4.2.3 Results of docking Inhibitors with CD209 Isoform 4 in AUTODOCK Vina: 
 
 
                                    
Table 33: CID 60855 Table 34: CID 58974096          Table 35: CID 59464423                Table 36: CID 60076457 
 
 
                                      
Table 37: CID 71753010           Table 38: CID 448825           Table 39: CID 17754024                Table 40: CID 23422347 
 
 
                                
Table 41: CID 46936304         Table 42: CID 49852385  Table 43: CID 448003 
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4.2.4 Results of docking Inhibitors with CD209 Isoform 5 in AUTODOCK Vina 
 
 
                                          
Table 44: CID 60855       Table 45: CID 58974096           Table 46: CID 59464423                  Table 47: CID 60076457 
 
                                             
Table 48: CID 71753010                Table 49: CID 448825             Table 50: CID 17754024                 Table 51: CID 23422347 
 
 
                            
Table 52: CID 46936304                 Table 53: CID 49852385                 Table 54: CID 448003 
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4.3 Summary Of All The Docking Results From Autodock Vina 
 
Table 55: Summary Of All The Docking Results From Autodock Vina 
 
 
Sr. 
No. 
 
Ligand 
 
 
Receptor 
 
 
 
 
PubChem ID 
 
Also known as 
 
CD209 antigen isoforms [Homo sapiens] 
 
(Binding energy in kcal/mol) 
 
    
1 
 
 
3 
 
4 
 
5 
 
1. 
 
CID 60855 
 
Zanamivir 
 
 
-8.0 
 
-7.8 
 
-10.0 
 
-7.8 
 
2. 
 
CID 58974096 
 
Talo-zanamivir 
 
 
-5.9 
 
-6.9 
 
-7.4 
 
-6.3 
 
3. 
 
 
CID 59464423 
 
SureCN12367840 
 
 
-5.8 
 
-6.0 
 
-7.3 
 
-6.3 
 
4. 
 
 
CID 60076457 
 
  
-5.5 
 
-6.2 
 
-7.6 
 
-6.2 
 
 
5. 
 
 
CID 71753010 
 
Zanamir-d3 
 
 
-5.6 
 
-6.3 
 
-6.7 
 
-6.0 
 
6. 
 
CID 448825 
 
HHA 
 
 
-4.1 
 
-4.7 
 
-5.9 
 
-4.8 
 
7. 
 
CID 17754024 
 
CHEBI:60840 
 
 
-5.0 
 
-5.2 
 
-6.1 
 
-5.2 
 
8. 
 
CID 23422347 
 
CTK0H0810 
 
 
-5.0 
 
-5.1 
 
-6.2 
 
-5.2 
 
9. 
 
CID 46936304 
 
SureCN4317430 
 
 
-4.8 
 
-5.2 
 
-6.3 
 
-5.1 
 
10. 
 
CID 49852385 
 
CPD-9518 
 
 
-4.7 
 
-5.1 
 
-6.2 
 
-5.2 
 
11. 
 
CID 448003 
 
 
UDA 
 
-12.4 
 
-13.2 
 
-13.0 
 
-13.3 
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4.4 Toxicity Report Of All The Inhibitors From ChemBio Server. 
 
Table 56: Toxicity Report of all the Inhibitors 
Sr. No.  
PubChem ID 
 
 
Report 
1  
CID 60855 
 
 
Non-toxic 
2  
CID 58974096 
 
 
Non-toxic 
3  
CID 59464423 
 
 
Non-toxic 
4  
CID 60076457 
 
 
Non-toxic 
5  
CID 71753010 
 
 
Non-toxic 
6  
CID 448825 
 
 
Non-toxic 
7  
CID 17754024 
 
 
Non-toxic 
8  
CID 23422347 
 
 
Non-toxic 
9  
CID 46936304 
 
 
Non-toxic 
10  
CID 49852385 
 
 
Non-toxic 
11  
CID 448003 
 
 
Non-toxic 
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 5. CONCLUSION 
 
DENV is able to infect many types of host cells and this resulted in the identification of several 
putative DENV receptors. DCs in the skin are believed to be the first target cells, and therefore DC 
SIGN is assumed to be the most important DENV receptor until now. Preventing the entry of DENV  
into the host cell can be a very good method to inhibit dengue fever. Carbohydrate Binding 
Agents(CBAs) are considered effective against inhibiting viral entry  into the host cell. We selected 
such CBAs like Hippeastrum hybrid (HHA), Galanthus nivalis (GNA), and Urtica dioica (UDA), 
isolated from the amaryllis, snowdrop, and stinging nettle respectively, along with their analogues to 
check their binding energy with the CD209 isoforms using AutoDock vina. From the results, we can 
conclude that Urtica dioica (UDA) amongst all the inhibitors used have shown the least binding 
energy (-13.1 kcal/mol) and hence can be used as a potential drug in inhibiting DENV entry into the 
DCs and hence prevent dengue. These results prove that entry inhibitors can prove effective in 
developing drugs against dengue and hence this indicates a very important feature for further 
development of entry inhibitors and for future clinical studies.  
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